Oura to Acquire AI Primary Care Firm Counsel Health for $625 Million

Oura has agreed to acquire AI primary care company Counsel Health for $625 million, the company announced, in a deal that will put board-certified physicians and a 24/7 medical AI service inside the Oura app. The acquisition, which Oura expects to close by the end of the year, marks the most aggressive step yet in the smart ring maker's transformation from a wearable seller into a direct healthcare provider.

The $625 million price tag is the number that anchors this story. It buys Oura a company that was already a partner in its app, not a stranger. Counsel Health brings in-house physicians, around-the-clock medical AI, and the ability to issue what the press release describes as "prescriptions for episodic health conditions." For Oura users, that could mean asking a physician for help through the app the next time a cold hits, rather than booking a same-day appointment that may not exist.

Why is Oura buying a medical company?

Oura CEO Tom Hale describes the company's ambition as building "a doctor in your pocket." The Oura Ring began its life as a sleep tracker. It has since grown into a continuous health monitor that watches for deviations from a user's biometric baseline — a spiked resting heart rate, a higher body temperature — often before the user feels any symptoms.

That detection capability has a gap, and Oura knows it. The ring can tell you something is off. It cannot tell you what to do about it. The acquisition of Counsel Health is designed to close that loop, connecting the ring's warnings to clinical guidance, physician consultations, and prescriptions.

David Shuman, executive chairman of Oura, framed the strategic logic in a press release: "Oura tells members what's happening in their bodies, and Counsel helps them act on it. This combination expands our addressable market and deepens the value we deliver to every member."

That quote carries the business case in two clauses. Detection plus action equals a larger addressable market, and deeper value means higher retention and, potentially, higher subscription revenue per member.

What exactly does Counsel Health add?

According to the announcement, the deal brings three concrete capabilities to Oura members:

• Access to Counsel Health's in-house physicians, described as board-certified doctors.
• A 24/7 medical AI service for timely health problems and support.
• "Prescriptions for episodic health conditions," plus specialty and chronic care for conditions including reproductive, aging, and cardiometabolic-related conditions.

The chronic care component matters as much as the episodic one. A ring that flags a one-night temperature spike serves the worried well; a service that supports cardiometabolic conditions serves people managing lifelong health issues, a far larger and stickier market. Oura's 24/7 monitoring detects deviations from a user's biometric baseline, and the Counsel partnership builds on those capabilities by adding clinical interpretation on top.

What does this mean for the smart ring market?

The wearables industry has spent a decade generating health data that largely dead-ends at the user's screen. ZDNET's coverage of the deal highlights a familiar frustration: a ring can flag a health concern, but when the user shows that data to a care provider, the provider "may shrug them off." The data is collected continuously but acted on rarely.

Counsel Health changes that equation for Oura. Medical AI and in-house physicians can contextualize a user's biometrics when the user is sick or managing a chronic condition, turning passive measurements into clinical follow-up.

There is also a systems-level argument. In high-demand markets such as New York, the press coverage notes, it is notoriously difficult to get a same-day, in-person appointment with a primary care provider, which often leaves urgent care clinics as the only in-person option. ZDNET's reporter, a regular urgent care patient in Brooklyn, raises the question of whether app-based physicians could ease demand on those clinics — and hopes so. Making a physician readily available to Oura users could, in theory, reduce dependence on primary or urgent care providers.

That "in theory" is doing honest work. Whether app-based prescriptions and AI triage actually divert patients from urgent care is unproven, and the source does not claim otherwise.

What happens to pricing and access?

One significant question remains open. It is unknown whether access to Counsel Health physicians or the 24/7 medical AI will be included in an Oura app subscription, according to the report. Oura already sells its ring hardware and charges a subscription for full app features; adding physician access could arrive as a bundled perk, a premium tier, or a separate paid service. The company has not said.

The deal's structure and closing timeline are clear: the acquisition is expected to close by the end of the year.

A year of acquisitions

The Counsel Health deal is Oura's third acquisition this year, a pace that signals deliberate consolidation rather than opportunistic dealmaking. The previous two purchases:

• Galen AI, a conversational and personal health platform that connects smart ring data to medical records.
• Doublepoint AI, an AI-driven biometric and gesture recognition company that could add voice or gesture controls to Oura's next smart ring.

Taken together, the three deals sketch a roadmap. Galen AI links ring data to medical records. Doublepoint AI could change how users interact with the device itself. Counsel Health supplies the clinical layer — doctors, medical AI, prescriptions. Each acquisition fills a different layer of the "doctor in your pocket" stack Hale has described.

The stakes extend beyond one company. Apple, Samsung, and Google all sell health-tracking wearables; none has fully bridged the gap between consumer biometric data and physician-level care within a single app. If Oura closes that loop first, and the deal clears by year's end as expected, the $625 million question is whether consumers will pay for a ring that does not just measure their health but treats it — and whether regulators, insurers, and healthcare systems will follow.